TNFSF11 and hyperphosphatemia: Of note, the 2 of 4 1α,25(OH)2D3-treated mice in the control IgG-pretreated group exhibited severe hyperphosphatemia (>15 mg/dL), whereas 1α,25(OH)2D3 did not induce hyperphosphatemia in any of the anti-RANKL antibody-pretreated mice (Fig. 3B).